This week, the ratings of three pharmaceutical stocks on Portfolio Grader are down. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).

This week, Alcobra Ltd. (ADHD) falls to a D (“sell”), worse than last week’s grade of C (“hold”). In Portfolio Grader’s specific subcategories of Earnings Momentum, Equity and Cash Flow, ADHD also gets an F. As of Oct. 24, 2014, 10.5% of outstanding Alcobra Ltd. shares were held short. Trade volume is up 522.5% from the previous week. For more information, get Portfolio Grader’s complete analysis of ADHD stock.

Lipocine, Inc. (LPCN) ratings are on the decline this week as the company earns an F (“strong sell”). Last week, it received a D (“sell”). Lipocine is engaged in the development of pharmaceutical products in the areas of men’’s and women’’s health. The stock gets F’s in Earnings Revisions, Equity and Cash Flow. Trade volume is up 464.2% from the previous week. To get an in-depth look at LPCN, get Portfolio Grader’s complete analysis of LPCN stock.

Aratana Therapeutics, Inc. (PETX) earns an F this week, moving down from last week’s grade of D. The stock gets F’s in Equity and Cash Flow. For more information, get Portfolio Grader’s complete analysis of PETX stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.